University of Iowa, Iowa City.
Fairfax Family Practice Residency, Fairfax, Virginia.
JAMA. 2018 Jun 26;319(24):2521-2531. doi: 10.1001/jama.2018.7498.
By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 year. The prevalence of primary osteoporosis (ie, osteoporosis without underlying disease) increases with age and differs by race/ethnicity. With the aging of the US population, the potential preventable burden is likely to increase in future years.
To update the 2011 US Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis.
The USPSTF reviewed the evidence on screening for and treatment of osteoporotic fractures in men and women, as well as risk assessment tools, screening intervals, and efficacy of screening and treatment in subgroups. The screening population was postmenopausal women and older men with no known previous osteoporotic fractures and no known comorbid conditions or medication use associated with secondary osteoporosis.
The USPSTF found convincing evidence that bone measurement tests are accurate for detecting osteoporosis and predicting osteoporotic fractures in women and men. The USPSTF found adequate evidence that clinical risk assessment tools are moderately accurate in identifying risk of osteoporosis and osteoporotic fractures. The USPSTF found convincing evidence that drug therapies reduce subsequent fracture rates in postmenopausal women. The USPSTF found that the evidence is inadequate to assess the effectiveness of drug therapies in reducing subsequent fracture rates in men without previous fractures.
The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. (B recommendation) The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteoporotic fractures in men. (I statement).
到 2020 年,预计美国有超过 1230 万名年龄在 50 岁以上的人患有骨质疏松症。骨质疏松性骨折,特别是髋部骨折,与活动受限、慢性疼痛和残疾、丧失独立性以及生活质量下降有关,21%至 30%经历髋部骨折的患者在 1 年内死亡。原发性骨质疏松症(即无基础疾病的骨质疏松症)的患病率随年龄增长而增加,且因种族/民族而异。随着美国人口老龄化,未来几年潜在的可预防负担可能会增加。
更新 2011 年美国预防服务工作组(USPSTF)关于骨质疏松症筛查的建议。
USPSTF 审查了男性和女性骨质疏松性骨折筛查和治疗、风险评估工具、筛查间隔以及筛查和治疗在亚组中的疗效的证据。筛查人群为绝经后女性和无已知既往骨质疏松性骨折且无已知合并症或与继发性骨质疏松症相关药物使用的老年男性。
USPSTF 发现有确凿证据表明,骨测量测试可准确检测骨质疏松症和预测男性和女性的骨质疏松性骨折。USPSTF 发现有足够的证据表明,临床风险评估工具在识别骨质疏松症和骨质疏松性骨折风险方面具有中等准确性。USPSTF 发现确凿证据表明,药物治疗可降低绝经后妇女的后续骨折率。USPSTF 发现,没有足够的证据评估药物治疗在降低无既往骨折男性的后续骨折率方面的有效性。
USPSTF 建议使用骨测量测试筛查骨质疏松症,以预防女性 65 岁及以上人群的骨质疏松性骨折。(B 级推荐)USPSTF 建议使用骨测量测试筛查骨质疏松症,以预防有骨质疏松症风险的绝经后女性(通过正式的临床风险评估工具确定)发生骨质疏松性骨折。(B 级推荐)USPSTF 得出结论,目前的证据不足以评估筛查骨质疏松症以预防男性骨质疏松性骨折的利弊平衡。(I 级声明)。